MECHANISMS OF NON-RESPONSE TO ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: PERIPHERAL PROTEOMIC AND TRANSCRIPTOMIC PROFILING FROM THE SERENE-CD AND SERENE-UC STUDIES

Julian PanĂ©s  1     Bram Verstockt  2     Valerie Pivorunas  3     James Butler  4     Naim Mahi  4     Melanie Ruzek  3     Thierry Sornasse  5     James Fann  3     Feng Hong  3     Xiaohong Cao  6     Nizar Smaoui  4     Justin Wade Davis  4     Jasmina Kalabic  7     Alexandra Song  4     Azucena Salas  1     Tariq Ahmad  8     Severine Vermeire  2     Heath M. Guay  3     Nick Kennedy  8    
1 Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
2 University Hospitals Leuven, Catholic University of Leuven, Leuven, Belgium
3 AbbVie Bioresearch Center, Worcester, United States
4 AbbVie Inc., North Chicago, United States
5 AbbVie Redwood City, Redwood City, United States
6 AbbVie Cambridge Research Center, Cambridge, United States
7 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
8 Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom

Topic
IBD, Immunology

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing